Nonviral Gene Therapy and its Delivery Systems

Authors: Ma H.; Diamond S.L.

Source: Current Pharmaceutical Biotechnology, Volume 2, Number 1, March 2001 , pp. 1-17(17)

Publisher: Bentham Science Publishers

Abstract:

Nonviral gene therapy has significant clinical potential, yet itstherapeutic utility has been hindered by low transfection efficiency due to acombination of extracellular and intracellular barriers. Recent developments informulation and delivery methodology have allowed a number of advances towardhigh efficiency gene delivery to various cell types and organs. In particular, theextracellular and intracellular pharmacokinetics of plasmid DNA trafficking are better understood in a number of cell systems. Using cationic lipid or polymers (often with receptortargeting), more than 10 5 plasmids can be delivered to a single cell. Endosomolytic agents promote endosomedisruption, and include weak bases, proton-sponge polymers, fusogenic peptides, viral particles, andphotosensitizing compounds. Both classical and nonclassical nuclear localization signal (NLS) peptides havealso been tested for enhancement of the probability of nuclear import events, a major rate-limiting step inDNA delivery to nondividing cells. For example, the M9 sequence from heterogeneous nuclearribonucleoprotein A1 (hnRNP A1) protein, a non-classical NLS, has been found to increase gene expressionlevel by more than 10 to 150-fold in a variety of cell types. This review will concentrate on the currentunderstandings of the basic mechanisms of nonviral gene delivery and new approaches in the field.

Keywords: Nonviral Gene Therapy; Plasmid DNA; Pharmacokinetics; Endosomolytic agents; Endosome disruption; Photosensitizing compounds; Nonclassical nuclear localization signal; Fusogenic peptides; Fusogenic peptides; Proton-sponge polymers; M9 sequence

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201013378770

Publication date: 2001-03-01

• Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

• In this: publication
• By this: publisher
• In this Subject: Nutrition & Food ,  Biotechnology ,  Pharmacology
• By this author: Ma H. ;  Diamond S.L.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers